ReviewFrontiers in oncology2026
Decoding the role of non-coding RNAs in HNSCC radioresistance: molecular mechanisms and clinical implications.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinomas (HNSCC) are the sixth most commonly diagnosed cancer globally, with a stagnant five-year survival rate of approximately 50%. Risk factors include human papillomavirus (HPV) infection, smoking, alcohol consumption, and betel nut chewing, contributing to its genetic and molecular heterogeneity. Although radiotherapy is a primary treatment modality for locally advanced or inoperable HNSCC, the inherent radioresistance of tumor tissues limits its effectiveness, emphasizing the need for strategies to enhance radiosensitivity. Emerging evidence highlights the critical role of non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), in regulating tumor radiosensitivity by modulating cell cycle, DNA damage response (DDR), cell proliferation, invasion, and migration. This review systematically examines the molecular mechanisms and clinical significance of ncRNAs in the radioresistance of HNSCC, summarizing 118 ncRNAs (from 103 articles), including 31 radioresistant miRNAs, 51 radiosensitive miRNAs, 22 radioresistant lncRNAs, 4 radiosensitive lncRNAs, 7 radioresistant circRNAs, and 3 radiosensitive circRNAs. Furthermore, this study discusses the potential roles of ncRNAs, specifically their use as predictive biomarkers for response to radiotherapy and as therapeutic targets in precision oncology. By integrating molecular insights with clinical perspectives, this review provides a valuable framework for understanding ncRNA-mediated radioresistance and proposes new strategies to overcome the challenges in improving HNSCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.